Precision medicine

The FLEX breast cancer registry intends to collect complete information on 10,000 patients over the course of 10 years

Newly discovered genetic alterations could indicate whether treatment or active surveillance is the best option for low-risk prostate cancer patients

Luxembourg’s new molecular diagnostics program aims to establish the value of such analyses as a part of routine cancer care

To harness liquid biopsy’s many advantages, it’s vital to ensure appropriate testing – and cfDNA synthetic plasma reference standards can help

The spatial arrangement of immune cells could predict whether aggressive chemotherapy is the best option for patients with early-stage lung cancer

An electronic gas-sensing capsule may increase diagnostic and monitoring accuracy in disorders of the digestive tract

Markers such as DNA methylation, analyzed by liquid biopsy, may improve on ovarian cancer testing options like gold standard CA125

A collaboration between industry, academia, and the clinic could lead to more efficient, more personalized cancer diagnosis and treatment

New biomarker sensing technology can detect miniscule concentrations of molecules in the blood to assist with patient monitoring

Epigenetics may combine with liquid biopsy to offer an effective way of detecting early-stage cancers and recurrences